Fig. 1: Clinical data from TNBC patients. | Nature Communications

Fig. 1: Clinical data from TNBC patients.

From: Chimeric exosomes-derived immunomodulator restoring lymph nodes microenvironment for sensitizing TNBC immunotherapy

Fig. 1

a Illustrative representation of nLNs and mLNs from TNBC patients. b Kaplan-Meier plots of overall survival (OS) categorizing TNBC patients by LNs’ stage (Log-rank P value < 0.0001). N0 samples (n = 1536), N1 samples (n = 945), N2 samples (n = 190), N3 samples (n = 178). c MRI images depicting the primary tumor and mLNs in TNBC patients, with red arrows highlighting the affected areas. d Histopathological comparison between the nLNs and mLNs using H&E staining. e Immunohistochemistry (IHC) analysis of Foxp3 in the nLNs versus mLNs. f CLSM showcasing the co-localization of CD11c (red) with BODIPY (green) in the nLNs versus mLNs. g Multiplex IHC for immune profiling in the nLNs and mLNs from the TNBC patient (n = 4 independent experiments). Scale bar=100 μm. h Clustering analysis of immune cells in matched nLNs and mLNs’ samples from the TNBC patient. i Gene Ontology (GO) enrichment analysis of gene expression variations in DCs within the mLNs vs nLNs. P values are derived from one-sided Fisher’s Exact Test for pathway and GO enrichment. Source data are provided as a Source Data file.

Back to article page